Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Boston Scientific Corporation. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Why Is Boston Scientific Corporation (BSX) Under Investigation?
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of shareholders of Boston Scientific Corporation (NYSE: BSX).
On October 28, 2026, Boston Scientific reported its Q3 2026 financial results, missing analyst consensus estimates on earnings per share. The Company also lowered its sales and earnings guidance for the third consecutive quarter. Management attributed the severe guidance revision to operational fallout and remediation costs stemming from a major cybersecurity incident, alongside structural challenges in its key Watchman heart device and electrophysiology segments. Following this news, Boston Scientific’s stock price fell $2.63 per share, or 5.84%, to close at $42.43 per share on October 28, 2026.
What Potential Securities Violations Is BG&G Investigating?
- Whether Boston Scientific Corporation and certain of its officers made false or misleading statements regarding the Company's financial condition and business prospects.
- Whether Boston Scientific Corporation failed to disclose material adverse information that would have been significant to a reasonable investor.
- Whether the Company's earnings guidance was supported by a reasonable factual basis at the time it was made.
What Should Boston Scientific Corporation (BSX) Investors Do?
How Is Boston Scientific Corporation (NYSE: BSX) Stock Trading Today?
How Does BG&G Help Investors in Securities Fraud Investigations?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
We handle cases on a contingency fee basis — we advance all litigation costs on your behalf. There is no fee unless we are successful.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”